This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perros, P. Articles by Dickinson, J. Search for Related Content PubMed PubMed Citation Articles by Perros, P. Articles by Dickinson, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Hormone Replacement Therapy Hazardous Substances DB LEVOTHYROXINE Related Collections Thyroid

A Prospective Study of the Effects of Radioiodine Therapy for Hyperthyroidism in Patients with Minimally Active Graves’ Ophthalmopathy

Endocrine Unit (P.P., S.F.), Freeman Hospital, Newcastle upon Tyne NE7 7DN, United Kingdom; School of Clinical Medical Sciences (P.K.-T.), University of Newcastle upon Tyne, Newcastle upon Tyne NE1 7RU, United Kingdom; and Department of Ophthalmology (C.N., J.D.), Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, United Kingdom

Address all correspondence and requests for reprints to: Dr. P. Perros, Endocrine Unit, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, United Kingdom. E-mail: petros.perros{at}ncl.ac.uk.

Context: Radioiodine is an effective and safe treatment for hyperthyroidism but has been implicated as a risk factor for deterioration or new presentation of Graves’ ophthalmopathy (GO). Prophylactic glucocorticoids appear to prevent this effect.

Objective: The objective of this study was to document the course of GO after radioiodine therapy.

Design: This was a prospective observational study. Patients were assessed at baseline and 2, 4, 6, and 12 months after radioiodine therapy.

Setting: The study was conducted at a tertiary referral center.

Patients: Seventy-two GO patients with minimally active eye disease participated in the study.

Intervention: A fixed dose of radioiodine was administered. T₄ was commenced 2 wk later to prevent hypothyroidism.

Main Outcome Measures: Change in activity and severity of GO were analyzed.

Results: Exophthalmometer readings, the width of the palpebral aperture, diplopia scores, and the clinical activity score improved significantly. By clinically significant criteria, the eye disease improved in four patients (transiently in three of the four cases), most likely attributable to the natural course of the disease. No patient’s eyes deteriorated.

Conclusions: Radioiodine is not associated with deterioration of GO in patients with minimally active eye disease when postradioiodine hypothyroidism is prevented.

This article has been cited by other articles:

				F. Traisk, L. Tallstedt, M. Abraham-Nordling, T. Andersson, G. Berg, J. Calissendorff, B. Hallengren, P. Hedner, M. Lantz, E. Nystrom, et al. Thyroid-Associated Ophthalmopathy after Treatment for Graves' Hyperthyroidism with Antithyroid Drugs or Iodine-131 J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3700 - 3707. [Abstract] [Full Text] [PDF]

				G. Vannucchi, I. Campi, D. Covelli, D. Dazzi, N. Curro, S. Simonetta, R. Ratiglia, P. Beck-Peccoz, and M. Salvi Graves' Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3381 - 3386. [Abstract] [Full Text] [PDF]

				P. Perros, C. Neoh, and J. Dickinson Thyroid eye disease BMJ, March 6, 2009; 338(mar06_1): b560 - b560. [Full Text]

				L. Bartalena and M. L. Tanda Graves' Ophthalmopathy N. Engl. J. Med., March 5, 2009; 360(10): 994 - 1001. [Full Text] [PDF]

				G. A. Brent Graves' Disease N. Engl. J. Med., June 12, 2008; 358(24): 2594 - 2605. [Full Text] [PDF]

				J. C. Sisson, M. J. Schipper, C. C. Nelson, J. E. Freitas, and B. R. Frueh Radioiodine Therapy and Graves' Ophthalmopathy J. Nucl. Med., June 1, 2008; 49(6): 923 - 930. [Abstract] [Full Text] [PDF]

				L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Eur. J. Endocrinol., March 1, 2008; 158(3): 273 - 285. [Full Text] [PDF]

				A. Iagaru and I. R. McDougall Treatment of Thyrotoxicosis J. Nucl. Med., March 1, 2007; 48(3): 379 - 389. [Abstract] [Full Text] [PDF]

				Radioiodine therapy for hyperthyroidism DTB, June 1, 2006; 44(6): 44 - 48. [Abstract] [Full Text] [PDF]

				L. Bartalena Glucocorticoids for Graves' Ophthalmopathy: How and When J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5497 - 5499. [Full Text] [PDF]